Eur Respir J 1996; 9: 456-462
Copyright © ERS Journals Ltd 1996
Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics
ZH Jaffar,
P Sullivan,
C Page,
and
J Costello
Theophylline has been shown by several investigators to attenuate the late asthmatic response (LAR) to inhaled allergen, suggesting that it has anti-inflammatory or immunomodulatory properties. We have, therefore, undertaken a double-blind, placebo-controlled study to examine the effects of low-dose theophylline on bronchoalveolar lavage (BAL) and blood T-lymphocyte profile and activation in asthmatics following antigen challenge and the development of a LAR. Peripheral blood and BAL samples were obtained from 17 subjects with mild atopic asthma before and after 6 weeks of treatment with either oral theophylline or placebo. The mean serum theophylline concentration achieved was 6.6 micrograms.mL-1, which is below the currently accepted therapeutic range. Following theophylline therapy, there was a significant decrease in the number of BAL lymphocytes compared to placebo. On flow cytometric analysis of BAL cells, a significant loss of CD3+ T-lymphocytes, comprising both CD4+ and CD8+ subsets, was demonstrated. Moreover, there was a decrease in the number of BAL CD4+ T-cells expressing the activation marker very late activation antigen-1 (VLA-1), and an apparent reduction in human leucocyte antigen-DR (HLA-DR). Correspondingly, this was accompanied in the blood by an elevation in the proportion of activated CD4+ T-lymphocytes, in particular those expressing HLA-DR. These findings provide further evidence that theophylline has an anti-inflammatory action in asthma.
This article has been cited by other articles:

|
 |

|
 |
 
M. Spears, I. Donnelly, L. Jolly, M. Brannigan, K. Ito, C. McSharry, J. Lafferty, R. Chaudhuri, G. Braganza, I. M. Adcock, et al.
Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study
Eur. Respir. J.,
May 1, 2009;
33(5):
1010 - 1017.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Barnes
Theophylline: New Perspectives for an Old Drug
Am. J. Respir. Crit. Care Med.,
March 15, 2003;
167(6):
813 - 818.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ito, S. Lim, G. Caramori, B. Cosio, K. F. Chung, I. M. Adcock, and P. J. Barnes
A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression
PNAS,
June 25, 2002;
99(13):
8921 - 8926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Lipworth, F. Chung, P. Barnes, and S. Lim
EFFECTS OF THEOPHYLLINE ON AIRWAY EOSINOPHILS
Am. J. Respir. Crit. Care Med.,
March 15, 2002;
165(6):
845 - 845.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Harbeck
Clin. Vaccine Immunol.,
May 1, 1998;
5(3):
271 - 277.
[Full Text]
|
 |
|
Copyright © 1996 by the European Respiratory Society.
|